Helenien 60% CAS NO.547-17-1 Xanthophyll, dipalmitate (7CI) b,e-Carotene-3,3'-diol, dihexadecanoate
TDS
547-17-1
Pharmaceutical Grade
60%
hongkong
LN
1kg\bag
2026-09-04
Semaglutide,Tirzepatide,Retatrutide,Pharmaceutical Peptide,Cosmetic peptide,Custom peptides
-
Product Description
-
Seller Information
-
DescriptionCertificatesBasic Info
-
Product Name:
Lutein dipalmitate
Other Name:β,ε-Carotene-3,3′-diol,3,3′-dihexadecanoate,(3R,3′R,6′R)-;Xanthophyll,dipalmitate;Helenien;β,ε-Carotene-3,3′-diol,dihexadecanoate,(3R,3′R,6′R)-;Adaptinol;Lutein dipalmitate;Xantophyll palmitate;Lutein palmitate;Xantofyl palmitate;Dipalmitoyllutein;Lutein bispalmitate;all-trans-Lutein dipalmitate;30508-47-5;20584-61-6
CAS No.:547-17-1
Molecular Formula:C72H116O4
InChIKeys:InChIKey=YHGJHDJZIOYZIR-URPSFYETSA-N
Molecular Weight:1045.69
Exact Mass:1045.69
EC Number:208-916-4
Categories:
Characteristics-
PSA:
52.6
XLogP3:28.53
Density:1.0±0.1 g/cm3
Melting Point:82 °C
Boiling Point:956.4±65.0 °C at 760 mmHg
Flash Point:462.1±32.7 °C
Refractive Index:1.524
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
Not classified.
GHS label elements, including precautionary statements
Pictogram(s) No symbol. Signal word No signal word
Hazard statement(s) none
Precautionary statement(s) Prevention none
Response none
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Semaglutide,Tirzepatide,Retatrutide,Pharmaceutical Peptide,Cosmetic peptide,Custom peptides
-
Location:
Room 1502, Unit 3, Building 2, Nanshan Garden, Jianye 2nd Road, Guodu Subdistrict, Chang'an District, Xi'an City, Shaanxi Province, P.R.China
-
Total Employees:
101-200
-
Year of Establishment:
2017
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
